Phase I/II Study of Veltuzumab Combined with 90Y-Epratuzumab Tetraxetan in Patients with Relapsed/Refractory, Aggressive Non-Hodgkin's Lymphoma

Study Status

Open to Enrollment

Study Description

This is a clinical trial for people with non-Hodgkin lymphoma (NHL) whose NHL has not responded adequately to standard treatments.

People with relapsed aggressive lymphoma can in some cases experience long term remission with aggressive chemotherapy treatments. However, there is no standard treatment for patients who either are not eligible for this aggressive treatment due to other health problems, or who have not responded well to chemotherapy, and better therapy options are needed.

The purpose of this study is to test the safety of 90Y-epratuzumab at different dose levels combined with veltuzumab. The study will also provide early evidence of how effective the combination of 90Y-epratuzumab and veltuzumab is in treating people with aggressive lymphomas who have not responded well to earlier treatment.

The treatment portion of this study consists of study drug administrations each week for 4 consecutive weeks. Participants will then return for study visits at intervals up to 12 weeks for blood samples and evaluation for 2 years, and then every 6 months for up to 5 years or until disease progression.



Key Eligibility

  • Men and women age 18 and older
  • CD20+ B-cell non-Hodgkin lymphoma (NHL), with diffuse large B-cell lymphoma (DLBCL) or other aggressive lymphomas
  • Progressed after or did not respond optimally to at least 1 prior standard treatment regimen for NHL
  • If DLBCL, ineligible for or refused high-dose chemotherapy with stem cell transplant
  • Detailed eligibility reviewed when you contact the study team

Principal Investigator

Peter Martin, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page